Posted by Michael Wonder on 19 Sep 2024
Valneva submits label extension applications for its chikungunya vaccine Ixchiq to EMA and Health Canada
18 September 2024 - To potentially include adolescents and antibody persistence up to two years.
Valneva today announced that it has submitted label extension applications to the EMA and Health Canada to potentially expand the use of its chikungunya vaccine, Ixchiq, to adolescents aged 12 to 17 years in Europe and Canada.
